Although, these previous findings suggest the potential prognostic value of using SLC20A1 expression for predicting late recurrence in patients with ER+ at early tumor stages, its relationship with tumor stage or endocrine therapy outcomes, and late recurrence remain to be clarified. The gene discussed is SLC20A1; the disease is neoplasm.